In a report released today, Frank Takkinen from Lake Street maintained a Buy rating on ClearPoint Neuro (CLPT – Research Report), with a price target of $22.00. The company’s shares closed yesterday at $9.10.
According to TipRanks, Takkinen is an analyst with an average return of -6.5% and a 38.64% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as TELA Bio, NeuroPace, and CVRx.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ClearPoint Neuro with a $18.00 average price target, a 97.80% upside from current levels. In a report released today, B.Riley Financial also maintained a Buy rating on the stock with a $14.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on ClearPoint Neuro’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.17 million and a GAAP net loss of $4.39 million. In comparison, last year the company earned a revenue of $4.28 million and had a GAAP net loss of $9.53 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Clearpoint Neuro, Inc. engages in the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain and heart. It conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform is comprises of ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Irvine, CA.
Read More on CLPT:
- ClearPoint Neuro to Present Investigational Research and Showcase Novel Innovations at the 26th American Society of Gene & Cell Therapy Annual Meeting in Los Angeles
- CLPT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023
- ClearPoint Neuro with teams with NE Scientific on software solution
- ClearPoint Neuro Announces Agreement with NE Scientific to Integrate Gene Therapy Infusion Coverage Tool into ClearPoint Maestro® Brain Model
